DK0782445T3 - Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed - Google Patents

Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed

Info

Publication number
DK0782445T3
DK0782445T3 DK95931014T DK95931014T DK0782445T3 DK 0782445 T3 DK0782445 T3 DK 0782445T3 DK 95931014 T DK95931014 T DK 95931014T DK 95931014 T DK95931014 T DK 95931014T DK 0782445 T3 DK0782445 T3 DK 0782445T3
Authority
DK
Denmark
Prior art keywords
serotonin reuptake
reuptake inhibitor
opioid antagonist
selective serotonin
combination
Prior art date
Application number
DK95931014T
Other languages
Danish (da)
English (en)
Inventor
Leonard Cook
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Application granted granted Critical
Publication of DK0782445T3 publication Critical patent/DK0782445T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK95931014T 1994-09-19 1995-09-07 Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed DK0782445T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30885994A 1994-09-19 1994-09-19
PCT/US1995/010987 WO1996009047A1 (en) 1994-09-19 1995-09-07 Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence

Publications (1)

Publication Number Publication Date
DK0782445T3 true DK0782445T3 (da) 2002-05-06

Family

ID=23195683

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95931014T DK0782445T3 (da) 1994-09-19 1995-09-07 Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed

Country Status (11)

Country Link
US (1) US5958962A (es)
EP (1) EP0782445B1 (es)
AT (1) ATE214276T1 (es)
AU (1) AU3419995A (es)
CA (1) CA2197554A1 (es)
CO (1) CO4410317A1 (es)
DE (1) DE69525847T2 (es)
DK (1) DK0782445T3 (es)
HR (1) HRP950485A2 (es)
WO (1) WO1996009047A1 (es)
ZA (1) ZA957891B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001848A (en) * 1996-03-25 1999-12-14 The Regents Of The University Of California Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
ATE256457T1 (de) * 1997-07-01 2004-01-15 Pfizer Prod Inc In gelatine eingekapselte sertarline dosierungsformen
BR9810403A (pt) 1997-07-01 2000-08-29 Pfizer Sais da sertralina e formas de dosagem de liberação sustentada da sertralina
AU1018801A (en) * 1999-10-29 2001-05-14 Novo Nordisk A/S Use of 3,4-substituted piperidines
DK2283842T3 (en) * 2000-02-08 2015-05-26 Euro Celtique Sa Oral opioid agonist formulations secured against forgery
US7034036B2 (en) * 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
HUP0401022A3 (en) * 2001-08-14 2006-11-28 Biotie Therapies Corp Method for the preparation of pharmaceutical compositions containing opioid antagonist for treating alcoholism or alcohol abuse
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
CN1320886C (zh) 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
DE10237057A1 (de) * 2002-08-09 2004-03-25 Grünenthal GmbH Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
DK2316456T3 (en) 2003-04-29 2017-09-11 Orexigen Therapeutics Inc Compositions for affecting weight loss comprising an opioid antagonist and bupropion
JP2007526438A (ja) * 2003-06-06 2007-09-13 コンビナトルックス インコーポレイテッド 組成物の組み合わせの多次元評価システムおよび方法
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
EP1954316A1 (en) * 2005-11-28 2008-08-13 Orexigen Therapeutics, Inc. Methods of treating anxiety disorders
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
KR101654176B1 (ko) 2006-11-09 2016-09-09 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
US20100168119A1 (en) 2008-11-05 2010-07-01 Pharmorx, Inc. Compositions and methods for minimizing or reducing agonist-induced desensitization
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
ES2802048T3 (es) 2012-06-06 2021-01-15 Nalpropion Pharmaceuticals Llc Composición para uso en un método para el tratamiento de sobrepeso y obesidad en pacientes con alto riesgo cardiovascular
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
WO1992019241A1 (en) * 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5366990A (en) * 1991-11-14 1994-11-22 Reid Larry D Method for treating alcohol abuse and alcoholism
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

Also Published As

Publication number Publication date
ZA957891B (en) 1997-03-19
EP0782445B1 (en) 2002-03-13
ATE214276T1 (de) 2002-03-15
AU3419995A (en) 1996-04-09
CO4410317A1 (es) 1997-01-09
CA2197554A1 (en) 1996-03-28
DE69525847T2 (de) 2002-09-05
US5958962A (en) 1999-09-28
EP0782445A1 (en) 1997-07-09
WO1996009047A1 (en) 1996-03-28
HRP950485A2 (en) 1997-08-31
DE69525847D1 (de) 2002-04-18

Similar Documents

Publication Publication Date Title
DK0782445T3 (da) Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
WO2002038142A3 (en) Serotonergic compositions and methods for treatment of mild cognitive impairment
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
ATE250932T1 (de) Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
DE69213231T2 (de) Zusammensetzung und methode zur verstärkung der sonnenbräunung
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EA199700087A1 (ru) Способ ингибирования катепсина к
PT1039912E (pt) Agentes angiostaticos e composicoes para tratar glaucoma glc1a
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
ES2146249T3 (es) Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2.
FI954245A0 (fi) Koostumuksia ja menetelmiä immunovälitteisten tulehduksellisten häiriöiden hoitamiseksi
FI922551A0 (fi) Foerfarande foer skoetsel av septisk chock.
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
EA199800535A1 (ru) Способ лечения боли
ATE291909T1 (de) Verwendung der no-faenger, inhibitoren oder antagonisten zur behandlung von migraene
ATE270113T1 (de) Zusammenstellungen zur verbesserten wundheilung
ZA949564B (en) Method for treating constipation using dimeticone.
BR9609114A (pt) Composição inseticida de terra diatomácea
EA199800858A1 (ru) Способ лечения насморка или аллергического ринита
DE69838002D1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen, die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten